Gefitinib radiosensitizes non-small cell lung cancer cells through inhibition of ataxia telangiectasia mutated

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Park, Soo Yeon ^a,b   Kim, Young M ^a,b   Pyo, Hongryull ^a,b  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b National Cancer Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; CHECKPOINT KINASE 2; CYCLOOXYGENASE 2; GAMMA HISTONE H2AX; GEFITINIB; HISTONE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CELL CYCLE PROTEIN; DNA BINDING PROTEIN; PROTEIN SERINE THREONINE KINASE; QUINAZOLINE DERIVATIVE; RADIOSENSITIZING AGENT; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE REGULATION; CELL DEATH; CELL SPECIFICITY; CLONOGENIC ASSAY; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; INFRARED RADIATION; IONIZING RADIATION; LUNG NON SMALL CELL CANCER; MITOSIS; MULTINUCLEAR CELL; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; RADIATION EXPOSURE; RADIATION RESPONSE; RADIOSENSITIZATION; SIGNAL TRANSDUCTION; CELL CYCLE; DRUG ANTAGONISM; LUNG TUMOR; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

ATAXIA TELANGIECTASIA;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DNA-BINDING PROTEINS; HUMANS; LUNG NEOPLASMS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; QUINAZOLINES; RADIATION-SENSITIZING AGENTS; TUMOR SUPPRESSOR PROTEINS;

EID: 77955802302     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-222     Document Type: Article

References (41)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer Statistics, 2009. CA Cancer J Clin 2009, 59:225-249. 10.3322/caac.20006, 19474385.
2. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001, 7:2958-2970.
3. Feld R, Sridhar SS, Shepherd FA, Mackay JA, Evans WK. Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a systematic review. J Thorac Oncol 2006, 1:367-376. 10.1097/01243894-200605000-00018, 17409886.
4. Hida T, Ogawa S, Park JC, Park JY, Shimizu J, Horio Y, Yoshida K. Gefitinib for the treatment of non-small-cell lung cancer. Expert Rev Anticancer Ther 2009, 9:17-35. 10.1586/14737140.9.1.17, 19105704.
5. Jiang H. Overview of gefitinib in non-small cell lung cancer: an Asian perspective. Jpn J Clin Oncol 2009, 39:137-150. 10.1093/jjco/hyn139, 19088154.
6. Ochs JS. Rationale and clinical basis for combining gefitinib (IRESSA, ZD1839) with radiation therapy for solid tumors. Int J Radiat Oncol Biol Phys 2004, 58:941-949.
7. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995, 19:183-232. 10.1016/1040-8428(94)00144-I, 7612182.
8. Tanaka T, Munshi A, Brooks C, Liu J, Hobbs ML, Meyn RE. Gefitinib radiosensitizes non-small cell lung cancer cells by suppressing cellular DNA repair capacity. Clin Cancer Res 2008, 14:1266-1273. 10.1158/1078-0432.CCR-07-1606, 18281562.
9. She Y, Lee F, Chen J, Haimovitz-Friedman A, Miller VA, Rusch VR, Kris MG, Sirotnak FM. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic index. Clin Cancer Res 2003, 9:3773-3778.
10. Bianco C, Tortora G, Bianco R, Caputo R, Veneziani BM, Damiano V, Troiani T, Fontanini G, Raben D, Pepe S, et al. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res 2002, 8:3250-3258.
11. Park JS, Jun HJ, Cho MJ, Cho KH, Lee JS, Zo JI, Pyo H. Radiosensitivity enhancement by combined treatment of celecoxib and gefitinib on human lung cancer cells. Clin Cancer Res 2006, 12:4989-4999. 10.1158/1078-0432.CCR-05-2259, 16914589.
12. Geoerger B, Gaspar N, Opolon P, Morizet J, Devanz P, Lecluse Y, Valent A, Lacroix L, Grill J, Vassal G. EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts. Int J Cancer 2008, 123:209-216. 10.1002/ijc.23488, 18386816.
13. Chapet O, Kong FM, Lee JS, Hayman JA, Ten Haken RK. Normal tissue complication probability modeling for acute esophagitis in patients treated with conformal radiation therapy for non-small cell lung cancer. Radiother Oncol 2005, 77:176-181. 10.1016/j.radonc.2005.10.001, 16256230.
14. Wynn RB, Mehta V. Reduction of treatment breaks and radiation-induced esophagitis and pneumonitis using amifostine in unresectable non-small cell lung cancer patients receiving definitive concurrent chemotherapy and radiation therapy: a prospective community-based clinical trial. Semin Oncol 2005, 32:S99-104. 10.1053/j.seminoncol.2005.03.017, 16015543.
15. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, Gibson KH. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002, 62:5749-5754.
16. Blank M, Mandel M, Keisari Y, Meruelo D, Lavie G. Enhanced ubiquitinylation of heat shock protein 90 as a potential mechanism for mitotic cell death in cancer cells induced with hypericin. Cancer Res 2003, 63:8241-8247.
17. Miranda EI, Santana C, Rojas E, Hernandez S, Ostrosky-Wegman P, Garcia-Carranca A. Induced mitotic death of HeLa cells by abnormal expression of c-H-ras. Mutat Res 1996, 349:173-182.
18. Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G. Cell death by mitotic catastrophe: a molecular definition. Oncogene 2004, 23:2825-2837. 10.1038/sj.onc.1207528, 15077146.
19. Roninson IB, Broude EV, Chang BD. If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist Updat 2001, 4:303-313. 10.1054/drup.2001.0213, 11991684.
20. de Bruin EC, Medema JP. Apoptosis and non-apoptotic deaths in cancer development and treatment response. Cancer Treat Rev 2008, 34:737-749. 10.1016/j.ctrv.2008.07.001, 18722718.
21. Lobrich M, Jeggo PA. The impact of a negligent G2/M checkpoint on genomic instability and cancer induction. Nat Rev Cancer 2007, 7:861-869. 10.1038/nrc2248, 17943134.
22. Iliakis G, Wang Y, Guan J, Wang H. DNA damage checkpoint control in cells exposed to ionizing radiation. Oncogene 2003, 22:5834-5847. 10.1038/sj.onc.1206682, 12947390.
23. Harper JW, Elledge SJ. The DNA damage response: ten years after. Mol Cell 2007, 28:739-745. 10.1016/j.molcel.2007.11.015, 18082599.
24. Kuo LJ, Yang LX. Gamma-H2AX - a novel biomarker for DNA double-strand breaks. In Vivo 2008, 22:305-309.
25. Dai Y, DeSano JT, Meng Y, Ji Q, Ljungman M, Lawrence TS, Xu L. Celastrol potentiates radiotherapy by impairment of DNA damage processing in human prostate cancer. Int J Radiat Oncol Biol Phys 2009, 74:1217-1225. 2745184, 19545787.
26. Iwasa T, Okamoto I, Suzuki M, Nakahara T, Yamanaka K, Hatashita E, Yamada Y, Fukuoka M, Ono K, Nakagawa K. Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines. Clin Cancer Res 2008, 14:6496-6504. 10.1158/1078-0432.CCR-08-0468, 18927289.
27. Kim YM, Park SY, Pyo H. Cyclooxygenase-2 (COX-2) negatively regulates expression of EGFR and causes resistance to gefitinib in COX-2 overexpressing cancer cells. Mol Cancer Res 2009, 7:1367-1377. 10.1158/1541-7786.MCR-09-0004, 19671676.
28. Rukazenkov Y, Speake G, Marshall G, Anderton J, Davies BR, Wilkinson RW, Mark Hickinson D, Swaisland A. Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different?. Anticancer Drugs 2009, 20:856-866. 10.1097/CAD.0b013e32833034e1, 19657272.
29. McKillop D, Partridge EA, Kemp JV, Spence MP, Kendrew J, Barnett S, Wood PG, Giles PB, Patterson AB, Bichat F, et al. Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor. Mol Cancer Ther 2005, 4:641-649. 10.1158/1535-7163.MCT-04-0329, 15827338.
30. Astsaturov I, Cohen RB, Harari PM. EGFR-targeting monoclonal antibodies in head and neck cancer. Curr Cancer Drug Targets 2006, 6:691-710. 10.2174/156800906779010191, 17168674.
31. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354:567-578. 10.1056/NEJMoa053422, 16467544.
32. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139. 10.1056/NEJMoa040938, 15118073.
33. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500. 10.1126/science.1099314, 15118125.
34. Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, Janne PA, Januario T, Johnson DH, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005, 23:5900-5909. 10.1200/JCO.2005.02.857, 16043828.
35. Miller VA, Riely GJ, Zakowski MF, Li AR, Patel JD, Heelan RT, Kris MG, Sandler AB, Carbone DP, Tsao A, et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 2008, 26:1472-1478. 10.1200/JCO.2007.13.0062, 18349398.
36. Janmaat ML, Rodriguez JA, Gallegos-Ruiz M, Kruyt FA, Giaccone G. Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells. Int J Cancer 2006, 118:209-214. 10.1002/ijc.21290, 16003751.
37. Romanowska M, Maciag A, Smith AL, Fields JR, Fornwald LW, Kikawa KD, Kasprzak KS, Anderson LM. DNA damage, superoxide, and mutant K-ras in human lung adenocarcinoma cells. Free Radic Biol Med 2007, 43:1145-1155. 10.1016/j.freeradbiomed.2007.07.004, 17854710.
38. Kashii T, Mizushima Y, Nakagawa K, Monno S, Yano S. Amplification of the N-myc oncogene in an adenocarcinoma cell line of the lung. Anticancer Res 1992, 12:621-624.
39. Kim YM, Lee EJ, Park SY, Cho KH, Kim JY, Pyo H. Cyclooxygenase-2 up-regulates ataxia telangiectasia and Rad3 related through extracellular signal-regulated kinase activation. Mol Cancer Res 2009, 7:1158-1168. 10.1158/1541-7786.MCR-08-0493, 19584262.
40. Shin YK, Park JS, Kim HS, Jun HJ, Kim GE, Suh CO, Yun YS, Pyo H. Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels. Cancer Res 2005, 65:9501-9509. 10.1158/0008-5472.CAN-05-0220, 16230415.
41. Kang HK, Lee E, Pyo H, Lim SJ. Cyclooxygenase-independent down-regulation of multidrug resistance-associated protein-1 expression by celecoxib in human lung cancer cells. Mol Cancer Ther 2005, 4:1358-1363. 10.1158/1535-7163.MCT-05-0139, 16170027.